NEWSROOM

124 results have been found

Corporate
Investors
Products

2020
2019
2018
2017
2016

January 16, 2020

Grifols to launch TAVLESSE^® in Europe and Turkey to continue reinforcing its commercial strategy and commitment to patients

December 12, 2019

Grifols launches XEMBIFY^® 20% subcutaneous immunoglobulin, a new Primary Immunodeficiency treatment

December 12, 2019

Grifols launches XEMBIFY^® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment

December 6, 2019

Grifols presents its latest Alzheimer’s clinical trial data

December 5, 2019

Grifols streamlines hospital pharmacy operations with new KIRO Fill^® technology and PharmacyKeeper enhancements

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.

INVESTORS